Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Phase 3 Completed 457 enrolled Arcutis Biotherapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.

Timeline

Start: 2021-07-08
Primary completion: 2022-04-06
Completion: 2022-04-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Roflumilast	Small molecule	0.3 %	Topical

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Summary

Timeline

Drugs

Indications